黄斑部病变治疗市场－全球产业规模、份额、趋势、机会和预测，按类型、疾病阶段、治疗类型、销售管道、地区和竞争格局划分（2020-2030 年预测）

全球黄斑部病变治疗市场将从2024年的141.9亿美元成长到2030年的229亿美元，复合年增长率为8.30%。黄斑部病变治疗涵盖一系列药物干预措施，主要包括抗血管内皮生长因子（抗VEGF）药物，以及其他旨在控制老年黄斑部病变（AMD）的辅助疗法。 AMD是一种进行性眼科疾病，会导致中心视力丧失。

主要市场驱动因素

全球黄斑部病变治疗市场主要受到老年黄斑部病变（AMD）在全球范围内日益增长的患病率以及治疗方法和药物研发的不断进步的显着推动。 AMD发病率的上升导致患者群体不断扩大，对有效干预措施的需求也随之增长。

主要市场挑战

长期治疗方案带来的巨大经济负担，尤其是反覆进行玻璃体内注射抗血管内皮生长因子（抗VEGF）药物，直接阻碍了全球黄斑部病变治疗市场的成长。这种经济压力构成了一大障碍，限制了患者获得必要治疗的机会，并给各个地区的医疗保健预算带来了相当大的压力。

主要市场趋势

针对干性老年黄斑部病变（AMD）的补体系统抑制剂的研发代表着一个显着的成长趋势，满足了巨大的未被满足的医疗需求。地图状萎缩是干性AMD的一种晚期形式，先前一直缺乏核准的疾病改善疗法。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球黄斑部病变治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（干性老年黄斑部病变、湿性老年黄斑部病变）
  • 依疾病阶段划分（早期AMD、中期AMD、晚期AMD）
  • 依治疗类型（药物、器械、手术）
  • 依销售管道（门诊手术中心、医院、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美黄斑部病变治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲黄斑部病变治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区黄斑部病变治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲黄斑部病变治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲黄斑部病变治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球黄斑部病变治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• PanOptica Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Aerie Pharmaceutical Inc.
• REGENXBIO Inc.
• Bayer AG
• Lineage Cell Therapeutics Inc

第十六章：策略建议

第17章调查会社について・免责事项

The Global Macular Degeneration Treatment Market will grow from USD 14.19 Billion in 2024 to USD 22.90 Billion by 2030 at a 8.30% CAGR. Macular degeneration treatments encompass a range of pharmacological interventions, primarily anti-vascular endothelial growth factor (anti-VEGF) agents, along with other supportive therapies designed to manage age-related macular degeneration (AMD), a progressive ophthalmic condition leading to central vision loss.

Key Market Drivers

The global macular degeneration treatment market is significantly propelled by the increasing worldwide prevalence of age-related macular degeneration and continuous advancements in therapeutic modalities and drug development. The rising incidence of AMD creates an expanding patient pool demanding effective interventions. For instance, according to Eye Health Central, in 2025, approximately 200 million people worldwide are living with some form of age-related macular degeneration, underscoring the vast and growing clinical need that drives market demand.

Key Market Challenges

The substantial economic burden associated with long-term treatment regimens, particularly the recurring intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents, directly hampers the growth of the global macular degeneration treatment market. This financial strain presents a significant barrier, limiting patient access to necessary therapies and placing considerable pressure on healthcare budgets across various regions. The chronic nature of age-related macular degeneration (AMD) necessitates ongoing treatment, often involving frequent injections, which accumulates substantial costs over time for individuals and health systems.

Key Market Trends

The development of complement system inhibitors for dry age-related macular degeneration (AMD) represents a significant growth trend, addressing a substantial unmet medical need. Geographic atrophy, an advanced form of dry AMD, previously lacked approved disease-modifying therapies. These novel inhibitors target specific components of the complement cascade, an immune pathway implicated in dry AMD's pathogenesis and progression. Such targeted treatments offer the potential to slow disease progression and preserve vision.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• PanOptica Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Aerie Pharmaceutical Inc.
• REGENXBIO Inc.
• Bayer AG
• Lineage Cell Therapeutics Inc

Report Scope:

In this report, the Global Macular Degeneration Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Macular Degeneration Treatment Market, By Type:

• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Macular Degeneration Treatment Market, By Stage of Disease:

• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Macular Degeneration Treatment Market, By Treatment Type:

• Drug
• Devices
• Surgery

Macular Degeneration Treatment Market, By Sales Channel:

• Ambulatory Surgical Centers
• Hospitals
• Other

Macular Degeneration Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Macular Degeneration Treatment Market.

Available Customizations:

Global Macular Degeneration Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Macular Degeneration Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
  • 5.2.2. By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
  • 5.2.3. By Treatment Type (Drug, Devices, Surgery)
  • 5.2.4. By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Macular Degeneration Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Stage of Disease
  • 6.2.3. By Treatment Type
  • 6.2.4. By Sales Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Macular Degeneration Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Stage of Disease
      • 6.3.1.2.3. By Treatment Type
      • 6.3.1.2.4. By Sales Channel
  • 6.3.2. Canada Macular Degeneration Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Stage of Disease
      • 6.3.2.2.3. By Treatment Type
      • 6.3.2.2.4. By Sales Channel
  • 6.3.3. Mexico Macular Degeneration Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Stage of Disease
      • 6.3.3.2.3. By Treatment Type
      • 6.3.3.2.4. By Sales Channel

7. Europe Macular Degeneration Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Stage of Disease
  • 7.2.3. By Treatment Type
  • 7.2.4. By Sales Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Macular Degeneration Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Stage of Disease
      • 7.3.1.2.3. By Treatment Type
      • 7.3.1.2.4. By Sales Channel
  • 7.3.2. France Macular Degeneration Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Stage of Disease
      • 7.3.2.2.3. By Treatment Type
      • 7.3.2.2.4. By Sales Channel
  • 7.3.3. United Kingdom Macular Degeneration Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Stage of Disease
      • 7.3.3.2.3. By Treatment Type
      • 7.3.3.2.4. By Sales Channel
  • 7.3.4. Italy Macular Degeneration Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Stage of Disease
      • 7.3.4.2.3. By Treatment Type
      • 7.3.4.2.4. By Sales Channel
  • 7.3.5. Spain Macular Degeneration Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Stage of Disease
      • 7.3.5.2.3. By Treatment Type
      • 7.3.5.2.4. By Sales Channel

8. Asia Pacific Macular Degeneration Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Stage of Disease
  • 8.2.3. By Treatment Type
  • 8.2.4. By Sales Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Macular Degeneration Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Stage of Disease
      • 8.3.1.2.3. By Treatment Type
      • 8.3.1.2.4. By Sales Channel
  • 8.3.2. India Macular Degeneration Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Stage of Disease
      • 8.3.2.2.3. By Treatment Type
      • 8.3.2.2.4. By Sales Channel
  • 8.3.3. Japan Macular Degeneration Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Stage of Disease
      • 8.3.3.2.3. By Treatment Type
      • 8.3.3.2.4. By Sales Channel
  • 8.3.4. South Korea Macular Degeneration Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Stage of Disease
      • 8.3.4.2.3. By Treatment Type
      • 8.3.4.2.4. By Sales Channel
  • 8.3.5. Australia Macular Degeneration Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Stage of Disease
      • 8.3.5.2.3. By Treatment Type
      • 8.3.5.2.4. By Sales Channel

9. Middle East & Africa Macular Degeneration Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Stage of Disease
  • 9.2.3. By Treatment Type
  • 9.2.4. By Sales Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Macular Degeneration Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Stage of Disease
      • 9.3.1.2.3. By Treatment Type
      • 9.3.1.2.4. By Sales Channel
  • 9.3.2. UAE Macular Degeneration Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Stage of Disease
      • 9.3.2.2.3. By Treatment Type
      • 9.3.2.2.4. By Sales Channel
  • 9.3.3. South Africa Macular Degeneration Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Stage of Disease
      • 9.3.3.2.3. By Treatment Type
      • 9.3.3.2.4. By Sales Channel

10. South America Macular Degeneration Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Stage of Disease
  • 10.2.3. By Treatment Type
  • 10.2.4. By Sales Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Macular Degeneration Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Stage of Disease
      • 10.3.1.2.3. By Treatment Type
      • 10.3.1.2.4. By Sales Channel
  • 10.3.2. Colombia Macular Degeneration Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Stage of Disease
      • 10.3.2.2.3. By Treatment Type
      • 10.3.2.2.4. By Sales Channel
  • 10.3.3. Argentina Macular Degeneration Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Stage of Disease
      • 10.3.3.2.3. By Treatment Type
      • 10.3.3.2.4. By Sales Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Macular Degeneration Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Pfizer Inc.
• 15.4. PanOptica Inc.
• 15.5. Bausch Health Companies Inc.
• 15.6. Regeneron Pharmaceuticals Inc.
• 15.7. Aerie Pharmaceutical Inc.
• 15.8. REGENXBIO Inc.
• 15.9. Bayer AG
• 15.10. Lineage Cell Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer